Peter Heydemann to Treatment Outcome
This is a "connection" page, showing publications Peter Heydemann has written about Treatment Outcome.
Connection Strength
0.030
-
Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 09 23; 390(10101):1489-1498.
Score: 0.020
-
Outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study. Clin Infect Dis. 2006 May 15; 42(10):1383-94.
Score: 0.009